SecBot SecBot
8-K ·Filed Jul 2, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001104659-26-080409
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a routine corporate presentation update with no new material information. Monitor upcoming catalysts: TILVANCE-301 interim ORR analysis, IOV-LUN-202 registrational data, and IOV-SAR-201 trial initiation in 2H 2026. The stock has shown strong positive drift on prior neutral filings, but this update alone does not provide a trading signal.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.31
T+0 close · Jul 2, 2026 · via day close
Latest settled
+154.99%
T+60 · $10.99
Vs SPY
+151.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $4.31entry
  2. T+1 · 4mo ago −2.78%α −3.66% · $4.19
  3. T+5 · 4mo ago +1.39%α +0.46% · $4.37
  4. T+20 · 4mo ago +8.82%α +9.23% · $4.69
  5. T+60 · 7w ago +154.99%α +151.42% · $10.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine administrative event. The presentation reiterates previously disclosed financial guidance (FY26 revenue $350M-$370M, Q2 2026 revenue $86M-$88M) and pipeline progress, including the TILVANCE-301 Phase 3 frontline melanoma trial and IOV-LUN-202 NSCLC registrational trial. No new material financial data or business developments were disclosed beyond what was already public.

Key Facts

  • Filed 8-K to update corporate presentation used at healthcare conferences and with analysts.
  • FY26 total revenue guidance reiterated at $350M-$370M.
  • Q2 2026 revenue guidance reiterated at $86M-$88M.
  • Cash position as of 3/31/26: ~$319M.
  • Over 90 authorized treatment centers for Amtagvi as of 05/07/26.
  • TILVANCE-301 Phase 3 frontline melanoma trial enrollment on track; N=670, 75+ sites globally.
  • IOV-LUN-202 registrational trial in NSCLC has Fast Track Designation; potential launch in 2H27.
  • IOV-SAR-201 Phase 2 registrational trial in soft tissue sarcomas to commence in 2Q 2026.
  • IOV-5001 (IL-12 tethered TIL) IND-cleared; Phase 1/2 basket trial to start 2H2026.
  • Cash position ~$319M as of 3/31/26, with runway into 2028.

Financial Impact

No new financial data disclosed. FY26 revenue guidance reiterated at $350M-$370M; Q2 2026 guidance at $86M-$88M. Cash position ~$319M as of 3/31/26.

revenuecash

Risk Factors

  • Clinical trial risks: TILVANCE-301, IOV-LUN-202, and IOV-SAR-201 may fail to meet endpoints.
  • Commercial execution risk: Amtagvi revenue growth may not meet guidance of $350M-$370M for FY26.
  • Regulatory risk: FDA feedback on NSCLC and sarcoma registrational trials could delay timelines.
  • Cash burn: ~$319M cash with runway into 2028, but profitability not yet achieved.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-080409
Document: tm2618989d1_8k.htm0001104659-26-080409
Document: 0001104659-26-080409-index-headers.html0001104659-26-080409
Document: 0001104659-26-080409-index.html0001104659-26-080409
Document: 0001104659-26-080409.txt0001104659-26-080409

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026